“Post-herpetic neuralgia”的搜索结果，显示 231-240 项，共有 11248 项

1. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

2. 血液科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

3. 放射科- 临床试验- 妙佑医疗国际

   ... after hospitalization. Finally, it will allow characterization of patient selection factors and processes for ticagrelor vs alternative OAP agents, carrying ...

4. 血液科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not ...

6. 血液科- 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

7. 外科 - 临床试验- 妙佑医疗国际

   The Post Approval Study (PAS) is gathering data on the Tether device and it's efficacy and safety. Pafolacianine For Localization Of Pediatric Extracranial ...

8. 血液科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

9. 丙型肝炎 - 症状与病因 - 妙佑医疗国际

   o�fl1]mr<;1k�mx4;1k�k,r{kw2A2in�fa� a�e4a�e4a�e4a�e4k,r{kw2A2in�fa� a�efocusa�e4a�e4k*(.d 1r:th9gayl�i15i;]b4c-lwr7-0o5;];];g/e"/_l-l5 3];]b];-] ...

10. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... post-neoadjuvant chemotherapy, and to evaluate the safety of multi-epitope HER2 vaccine given concurrently with T-DM1 maintenance therapy. A Study Of The ...